Simbrinza Suspension/ Drops
Product Images NDC 0065-4147

5 FDA label images from Alcon Laboratories, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Simbrinza (NDC 0065-4147). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alcon Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

8ml Carton

8ml Carton
SIMBRINZA (brinzolamide/brimonidine tartrate) ophthalmic suspension 1%/0.2% boxed label for an 8 mL sterile eye drop bottle. The label displays active ingredients, dosage form as ophthalmic suspension, manufacturer Alcon Laboratories, Inc., contact information, storage instructions, barcode, and product NDC 0065-4147-27.*
FDA Label Image

Brimonidine Chemical Structure (Brimonidine)

Brimonidine Chemical Structure (Brimonidine)
Chemical structure of the active ingredients in SIMBRINZA: brinzolamide and brimonidine tartrate. The diagram shows the molecular frameworks, including rings, functional groups, and stereochemistry for both compounds.*
FDA Label Image

Brinzolamide Chemical Structure (Brinzolamide)

Brinzolamide Chemical Structure (Brinzolamide)
Chemical structure of brinzolamide, the active ingredient in SIMBRINZA ophthalmic suspension.*
FDA Label Image

Figure 1 (Figure1)

Figure 1 (Figure1)
A bar chart showing intraocular pressure (IOP) change in mmHg over three time points: Week 2, Week 6, and Month 3. The chart compares IOP changes at 8 AM, 10 AM, 3 PM, and 5 PM for three treatments: SIMBRINZA, Brinzolamide, and Brimonidine. Bars indicate the degree of IOP reduction at each time point for each treatment.*
FDA Label Image

Figure 2 (Figure2)

Figure 2 (Figure2)
A bar chart titled 'Study 2' depicting intraocular pressure (IOP) change in mmHg over three time points: Week 2, Week 6, and Month 3. The chart compares IOP changes at 8 AM, 10 AM, 3 PM, and 5 PM for three treatments: SIMBRINZA, Brinzolamide, and Brimonidine, with SIMBRINZA showing the greatest IOP reductions at all time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.